BITRF

Healthcare Biotechnology

Biotron Limited

$0.02

+0.00 +0.00% today

Price History

Not enough data

Key Stats

Market Cap

59.60M

Avg Volume

2,351

52W High

$0.10

52W Low

$0.00

Div. Yield

0.0%

Valuation

P/B Ratio

30.43

P/S Ratio

113.34

EV/EBITDA

-37.35

EV/Revenue

110.39

Margins

Gross Margin 100.0%

Operating Margin (118.9%)

Net Margin (288.7%)

EBITDA Margin (295.5%)

Growth & Returns

Return on Equity

(87.4%)

Return on Assets

(41.2%)

Liquidity & Leverage

Current Ratio

1.94

Quick Ratio

1.92

Total Cash

1.55M

Total Debt

About

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 that is in Phase 2 clinical trial for the treatment of HIV-1, as well as to treat hepatitis C virus infections; and BIT-HBV001 to treat hepatitis B virus and hepatitis delta virus. It also develops preclinical drugs for viral diseases, such as dengue, zika, and influenza virus. The company was incorporated in 1999 and is based in Sydney, Australia.